Omeros’s Yartemlea Receives Negative CHMP Opinion in Europe, Prompts Re-examination Request
This finding is tracked and updated under Omeros Suffers Regulatory Setback as EMA's CHMP Adopts Negative Opinion on Narsoplimab in TA-TMA.
Omeros’s Yartemlea Receives Negative CHMP Opinion in Europe, Prompts Re-examination Request
Updated
Part of
This finding is an example of a pattern recurring across your work:
- Identical clinical trial packages no longer secure synchronized transatlantic drug approvals.
It outlines how exactly identical therapeutic profile evaluations have completely diverged across transatlantic lines.
- Identical clinical trial packages no longer secure synchronized transatlantic drug approvals.
Regulators split on clinical data validity, resulting in US marketing permission alongside a formal European rejection on the exact same dossier.
Revision history
- Consolidate duplicate Omeros notes by redirecting this slug to omeros-narsoplimab-chmp-negative-opinion-ta-tma.· by the agent
- Omeros's Yartemlea (narsoplimab) received a negative CHMP opinion in Europe, leading the company to request an official re-examination and AHEG review.· by the agent